Pages that link to "Q46533798"

The following pages link to Overexpression of the PSMB5 gene contributes to bortezomib resistance in T-lymphoblastic lymphoma/leukemia cells derived from Jurkat line (Q46533798):

Displaying 38 items.

• Trial Watch: Proteasomal inhibitors for anticancer therapy (Q28082910) (← links)
• Molecular mechanisms of bortezomib resistant adenocarcinoma cells (Q28478538) (← links)
• BAK and NOXA are critical determinants of mitochondrial apoptosis induced by bortezomib in mesothelioma (Q28533736) (← links)
• Characterization of dihydroartemisinin-resistant colon carcinoma HCT116/R cell line (Q31031641) (← links)
• The ubiquitin-activating enzyme E1 as a therapeutic target for the treatment of leukemia and multiple myeloma (Q33523956) (← links)
• Targeting the ubiquitin-proteasome pathway with inorganic compounds to fight cancer: a challenge for the future (Q34195083) (← links)
• The small heat shock protein B8 (HSPB8) confers resistance to bortezomib by promoting autophagic removal of misfolded proteins in multiple myeloma cells. (Q34227679) (← links)
• The resistance mechanisms of proteasome inhibitor bortezomib (Q34256126) (← links)
• Apigenin manipulates the ubiquitin-proteasome system to rescue estrogen receptor-β from degradation and induce apoptosis in prostate cancer cells. (Q34448480) (← links)
• Proteasome inhibitors in the treatment of multiple myeloma (Q34611676) (← links)
• RNAi screen of the druggable genome identifies modulators of proteasome inhibitor sensitivity in myeloma including CDK5 (Q34870566) (← links)
• Emerging role of carfilzomib in treatment of relapsed and refractory lymphoid neoplasms and multiple myeloma. (Q35009005) (← links)
• Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives (Q35836881) (← links)
• Targeting Notch1 and proteasome as an effective strategy to suppress T-cell lymphoproliferative neoplasms (Q36020893) (← links)
• Cytotoxic effects of bortezomib in myelodysplastic syndrome/acute myeloid leukemia depend on autophagy-mediated lysosomal degradation of TRAF6 and repression of PSMA1. (Q36141927) (← links)
• CNS uptake of bortezomib is enhanced by P-glycoprotein inhibition: implications for spinal muscular atrophy (Q36618001) (← links)
• From bortezomib to other inhibitors of the proteasome and beyond (Q36852277) (← links)
• Proteasome subunit expression analysis and chemosensitivity in relapsed paediatric acute leukaemia patients receiving bortezomib-containing chemotherapy (Q37233146) (← links)
• Perspectives in the treatment of multiple myeloma (Q38108391) (← links)
• Proteasome inhibitors - molecular basis and current perspectives in multiple myeloma (Q38202977) (← links)
• The future of proteasome inhibitors in relapsed/refractory multiple myeloma. (Q38246060) (← links)
• A reversible and highly selective inhibitor of the proteasomal ubiquitin receptor rpn13 is toxic to multiple myeloma cells (Q38444221) (← links)
• Impaired bortezomib binding to mutant β5 subunit of the proteasome is the underlying basis for bortezomib resistance in leukemia cells. (Q39469395) (← links)
• Characterization of bortezomib-adapted I-45 mesothelioma cells (Q39702665) (← links)
• Characterization of the ubiquitin-proteasome system in bortezomib-adapted cells (Q39882407) (← links)
• Glutaminase inhibitor CB-839 synergizes with carfilzomib in resistant multiple myeloma cells (Q41056091) (← links)
• The challenge of developing robust drugs to overcome resistance (Q43221173) (← links)
• Bortezomib delays the onset of factor VIII inhibitors in experimental hemophilia A, but fails to eliminate established anti-factor VIII IgG-producing cells (Q44236379) (← links)
• (Immuno)proteasomes as therapeutic target in acute leukemia (Q47131929) (← links)
• Proteasome-associated deubiquitinases and cancer (Q47161331) (← links)
• PSMB5 plays a dual role in cancer development and immunosuppression (Q47347202) (← links)
• Effects of PSMB5 on proliferation and bortezomib chemo-resistance in human myeloma cells and its related molecular mechanisms (Q49817162) (← links)
• Proteasome dysregulation in human cancer: implications for clinical therapies (Q50077966) (← links)
• Unbiased compound-protein interface mapping and prediction of chemoresistance loci through forward genetics in haploid stem cells (Q50417403) (← links)
• A Practical Review of Proteasome Pharmacology (Q64096816) (← links)
• Targeting the ubiquitin-proteasome system for cancer therapy (Q87038902) (← links)
• Chronic activation of endothelial MAPK disrupts hematopoiesis via NFKB dependent inflammatory stress reversible by SCGF (Q89518402) (← links)
• Silencing of SENP2 in Multiple Myeloma Induces Bortezomib Resistance by Activating NF-κB Through the Modulation of IκBα Sumoylation (Q92824692) (← links)